ArticleHuman vaccines & immunotherapeutics2012
Non-contact helium-based plasma for delivery of DNA vaccines. Enhancement of humoral and cellular immune responses.
Article in Human vaccines & immunotherapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Analysis of physical and biological delivery systems for DNA cancer vaccines and their translation to clinical development.Clinical and experimental vaccine research · 2024Review
- Low-Temperature Plasma Techniques in Biomedical Applications and Therapeutics: An Overview.International journal of molecular sciences · 2023Review
- Combined effect of heat and corona charge on molecular delivery to a T cell line in vitro.PloS one · 2023Article
- Nonthermal plasma as part of a novel strategy for vaccination.Plasma processes and polymers (Print) · 2020Review
- Membrane Oxidation in Cell Delivery and Cell Killing Applications.ACS chemical biology · 2017Review
- Direct Current Helium Plasma forPlasma medicine · 2017Article
- Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine.Experimental and therapeutic medicine · 2016Article
- Optimization of a plasma facilitated DNA delivery method.Bioelectrochemistry (Amsterdam, Netherlands) · 2015Article
- Article
- Electrogenetherapy of B16.F10 murine melanoma tumors with an interleukin-28 expressing DNA plasmid.Human vaccines & immunotherapeutics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Non-viral in vivo administration of plasmid DNA for vaccines and immunotherapeutics has been hampered by inefficient delivery. Methods to enhance delivery such as in vivo electroporation (EP) have demonstrated effectiveness in circumventing this difficulty. However, the contact-dependent nature of EP has resulting side effects in animals and humans. Noncontact delivery methods should, in principle, overcome some of these obstacles. This report describes a helium plasma-based delivery system that enhanced humoral and cellular antigen-specific immune responses in mice against an intradermally administered HIV gp120-expressing plasmid vaccine (pJRFLgp120). The most efficient plasma delivery parameters investigated resulted in the generation of geometric mean antibody-binding titers that were 19-fold higher than plasmid delivery alone. Plasma mediated delivery of pJRFLgp120 also resulted in a 17-fold increase in the number of interferon-gamma spot-forming cells, a measure of CD8+ cytotoxic T cells, compared with non-facilitated plasmid delivery. This is the first report demonstrating the ability of this contact-independent delivery method to enhance antigen-specific immune responses against a protein generated by a DNA vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.